Public Health England has published a report showing that between 2010 and 2013 there was a 6% increase in antibiotic prescriptions from 25.9 to 27.4 doses per 1,000 people per day. While the proportion of resistant infections remains the same as that seen in previous years, as the total number of infections has increased so the total number of resistant infections has risen.Read more
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding (MoU).Read more
A new ‘one stop shop’ providing regulatory advice for those working in the life sciences industry on regenerative medicines launched today within the Medicines and Healthcare Products Regulatory Agency’s (MHRA) Innovation Office.Read more
ABPI Chief Executive Stephen Whitehead comments on the publication of NICE’s draft guidance on Medicines Optimisation.Read more
Our website is currently experiencing scrolling issues when viewed using Internet Explorer 8. If you are experiencing problems with scrolling please upgrade to a later version of Internet Explorer or use Chrome or Firefox.
Board of Management